phospho-MAPKAPK5(Thr182)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 5504R
英文名称phospho-MAPKAPK5(Thr182)
中文名称磷酸化p38调节/激活蛋白激酶抗体
别 名p-PRAK(phospho Thr182); MAPKAPK5(phospho T182); MAP kinase-activated protein kinase 5; MAPKAP kinase 5; MAPKAPK5; mitogen-activated protein kinase-activated protein kinase 5; p38-regulated/activated protein kinase.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 信号转导 转录调节因子 激酶和磷酸酶
抗体来源Rabbit
克隆类型Polyclonal
phospho-MAPKAPK5(Thr182)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量52kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human MAPKAPK5 around the phosphorylation site of Thr182:LM(p-T)PQ
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-MAPKAPK5(Thr182)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
The serine/threonine kinase PRAK is activated in response to cellular stress and proinflammatory cytokines, through its phosphorylation by MAP kinases including MAPK1/ERK, MAPK14/p38 alpha, and MAPK11/p38 beta. PRAK has been reported to have a putative tumor suppressor function by mediating senescence upon activation by p38 in response to oncogenic ras. It is thought that phosphorylation of p53 by PRAK following activation of p38 MAPK by ras plays an important role in ras induced senescence and tumor suppression.
Function:
Tumor suppressor serine/threonine-protein kinase involved in mTORC1 signaling and post-transcriptional regulation. Phosphorylates FOXO3, ERK3/MAPK6, ERK4/MAPK4, HSP27/HSPB1, p53/TP53 and RHEB. Acts as a tumor suppressor by mediating Ras-induced senescence and phosphorylating p53/TP53. Involved in post-transcriptional regulation of MYC by mediating phosphorylation of FOXO3: phosphorylation of FOXO3 leads to promote nuclear localization of FOXO3, enabling expression of miR-34b and miR-34c, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent MYC translation. Acts as a negative regulator of mTORC1 signaling by mediating phosphorylation and inhibition of RHEB. Part of the atypical MAPK signaling via its interaction with ERK3/MAPK6 or ERK4/MAPK4: the precise role of the complex formed with ERK3/MAPK6 or ERK4/MAPK4 is still unclear, but the complex follows a complex set of phosphorylation events: upon interaction with atypical MAPK (ERK3/MAPK6 or ERK4/MAPK4), ERK3/MAPK6 (or ERK4/MAPK4) is phosphorylated and then mediates phosphorylation and activation of MAPKAPK5, which in turn phosphorylates ERK3/MAPK6 (or ERK4/MAPK4). Mediates phosphorylation of HSP27/HSPB1 in response to PKA/PRKACA stimulation, inducing F-actin rearrangement.
Subunit:
Interacts with ERK3/MAPK6 and ERK4/MAPK4 (via FRIEDE motif); the interaction is direct. Interacts with YWHAE; the interaction prevents phosphorylation of HSP27/HSPB1 leading to disrupt F-actin polymerization. Interacts with SQSTM1.
Subcellular Location:
Cytoplasm. Nucleus.
Tissue Specificity:
Expressed ubiquitously.
Post-translational modifications:
Phosphorylated on Thr-182 ERK3/MAPK6 or ERK4/MAPK4; which is the regulatory phosphorylation site and is located on the T-loop/loop 12, leading to activation. Phosphorylation at Thr-182 by p38-alpha/MAPK14, p38-beta/MAPK11 is subject to debate. Phosphorylated at Ser-115 by PKA/PRKACA, leading to localization to the cytoplasm. Autophosphorylated (By similarity).
Similarity:
Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family.
Contains 1 protein kinase domain.
SWISS:
Q8IW41
Gene ID:
8550
phospho-MAPKAPK5(Thr182)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-MAPKAPK5(Thr182)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 TXNDC4 内质网蛋白44抗体
合格 合格 Connexin-40 间隙连接蛋白40抗体
合格 NAP1L1 核小体组装蛋白1抗体
合格 合格 TTF1 甲状腺核转录因子-1抗体
合格 IL-1 Alpha Propeptide 白介素1α前肽/IL-1α前肽抗体
合格 CD55 衰变加速因子CD55抗体
合格 SLC27A1 长链脂肪酸转运蛋白1抗体
合格 GOT2 谷草转氨酶2抗体
合格 beta Amyloid 1-16 β淀粉样肽1-16/Aβ1-16抗体
合格 beta Amyloid 1-28 β淀粉样肽1-28/β-Amyloid 1-28抗体
合格 5HT2A Receptor 5-羟色胺受体2A抗体
合格 Centrin 1 中心体蛋白1抗体
合格 WASF3 Verprolin同源结构域包含蛋白3抗体
合格 合格 MMP13 基质金属蛋白酶13抗体
合格 NQO2 NAD(P)H 苯醌脱氢酶 2抗体
合格 FGL2 凝血酶原酶/维介素抗体
合格 PEPT1 肠道肽转运蛋白1/小肽转运蛋白1抗体
合格 Collagen II Ⅱ型胶原蛋白抗体
合格 ADH1C 乙醇脱氢酶1抗体
合格 CD45 白细胞共同抗原抗体
合格 CD45 白细胞共同抗原抗体
合格 NCOA1/KAT13A 核受体共激活剂1抗体
合格 合格 合格 Cytokeratin 5 细胞角蛋白5抗体
合格 合格 Dopamine Receptor D1 多巴胺受体D1抗体